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Fibrinogen and Markers of Fibrinolysis and Endothelial Damage 
Following Resolution of Critical Limb Ischaemia* 
K. R. Woodburn, A. Rumley, G. D. O. Lowe and d. G. Pollock 
Vascular Surgery Unit and University Department of Medicine, Royal Infirmary, Glasgow, Scotland, U.K. 
Objectives: To assess the effects of resolution of critical limb ischaemia on the elevated plasma fibrinogen, cross-linked 
fibrin degradation products (FDP), and von Willebrand factor antigen (vWF) levels, reported in peripheral arterial 
occlusive disease. 
Design: A prospective study of patients undergoing surgery for chronic critical limb ischaemia. 
Setting: Two vascular surgery units providing tertiary referral services for the West of Scotland. 
Materials: Venous blood samples were assayed for plasma fibrinogen, FDP D-dimer, and vWF levels, prior to surgery, 
together with fibrinolytic and rheologicaI parameters, in 82 patients. Sampling was repeated 4 months after resolution of 
critical limb ischaemia. 
Outcome measures: Levels of these parameters following successful resolution of critical limb ischaemia were compared 
with pre-operative l vels, and with an age-matched random population sample. 
Main results" Plasma flbrinogen and vWF levels were significantly lower (both p < 0.005, Wilcoxon matched pairs) 
following successful resolution of critical limb ischaemia in the 56 patients available for review, although levels remained 
higher than in population controls (p < 0.01, Mann-Whitney U-test). FDP levels were unchanged following surgery, 
remaining higher than in age-matched population controls (p < 0.01). 
Conclusions: Resolution of critical limb ischaemia f ils to reduce plasma fibrinogen, fibrin turnover, and vWF levels to 
those seen in population controls. This implies that increased fibrinogen and fibrin turnover in peripheral arterial disease 
is not solely a consequence of tissue ischaemia, while the persisting prothrombotic state following resolution of critical limb 
ischaemia had potentially important implications for graft and patient survival. 
Key Words: Fibrinogen; Endothelial damage; Critical limb ischaemia. 
Introduction 
A number of studies have indicated that blood 
rheology and plasma levels of fibrinogen and markers 
of fibrin turnover (cross-linked fibrin degradation 
products, FDP), together with the endothelial product 
von Willebrand Factor antigen (vWF), are abnormal in 
patients with symptomatic and asymptomatic periph- 
eral arterial disease, 1-6 while there is evidence that the 
elevation in levels of these potential thrombotic 
mediators is related to the severity of arterial dis- 
ease. 5'7"8 There is also evidence that elevated plasma 
fibrinogen and vWF levels are associated with, and 
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predictive of, graft occlusion. 9-12 Alterations in poten- 
tial thrombotic mediators may contribute to progres- 
sion of atherosclerosis and arterial occlusion by a 
variety, of means, 1B-17 although if they merely reflect 
biochemical derangement secondary to tissue ischae- 
mia, then resolution of critical imb ischaemia should 
reverse these potentially harmful alterations in blood 
rheology and levels of thrombotic mediators. 
In order to investigate this possibility, patients with 
28 critical limb ischaemia have been studied to deter- 
mine the effects of revascularisation r amputation 
surgery on the abnormal blood rheology observed in 
patients with peripheral arterial occlusive disease, and 
to determine whether or not levels of plasma fibrino- 
gen, FDP, vWF, factor VII, plasminogen activator 
inhibitor type-1 (PAI), and tissue plasminogen activa- 
tor (tPA), are returned to normal population levels 
following surgical resolution of critical limb 
ischaemia. 
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Materials and Methods 
Eighty-two in-patients with a diagnosis of critical imb 
ischaemia 18 were enrolled in the stud)~ and venous 
blood was sampled with minimal venous stasis prior 
to surgical intervention. Nine millilitres of blood from 
each sample were added to a plastic tube containing 
lml of trisodium citrate (0.109 M) and subsequently 
handled, stored, and assayed as previously described 6 
for plasma fibrinogen (Clauss assay), cross-linked FDP 
(D-dimer antigen, ELISA, Agen Ltd., Parsippan)~ New 
Jerse)~ U.S.A.), vWF (ELISA, Dako, High Wycombe, 
U.K.), Plasminogen Activator Inhibitor (chromogenic 
activity assa)~ KabiVitrum Ltd. Uxbridge, Middx., 
U.K.), and tissue Plasminogen Activator antigen 
(ELISA, Biopool TintElize, Biopool AB, Umea, Swe- 
den). Rheological variables were measured as pre- 
viously described 5 in blood anticoagulated with dipo- 
tassium edetate (1.5 mg/ml). The coefficients of 
variation for all of the above assays are below 10% in 
our laboratory. Serum albumin levels were determined 
on an Olympus AU 5200 analyser, using reagents 
supplied by Olympus and Boehringer Mann- 
heim (U.K. Ltd.). White cell count and haemoglobin 
were determined in a Coulter S counter, and red cell 
aggregation by a photometric assay (Myrenne GmbH, 
Roetgen, Germany). Plasma carboxyhaemoglobin lev- 
els were measured on dipotassium EDTA antico- 
agulated blood on a Co-Oximeter 282 (Instrumenta- 
tion Laboratory Ltd., Warrington, Cheshire, U.K.), 
within 6 h of sampling, non-smokers being confirmed 
by a plasma carboxyhaemoglobin of less than 
2.0% .19 
Patients were invited to attend for review 16 weeks 
after surgical treatment, and resolution of critical imb 
ischaemia was confirmed by relief of rest pain, 
resolution of infection and tissue healing, together 
with an increase in the ankle systolic pressure to above 
50 mmHg. In patients who had undergone amputa- 
tion, stump healing and relief of rest pain were taken 
as confirmatory of resolution of critical ischaemia. 
Venous blood samples were then obtained and proc- 
essed in the same manner as preoperative samples. 
Control samples were obtained from 80 subjects 
aged between 65 and 75 years of age (mean age 69 
years), who were assessed in local population studies 
(the first, second, and third WHO MONICA surveys). 
These studies were carried out in random samples of 
the population of North Glasgow, who, in this age 
range, would all be expected to have some athero- 
sclerotic arterial disease. Sample handling and storage 
were as previously described, and all assays were 
performed in the same laboratory, by the same 
methods, as samples from the patient population. 
Al l  statistical analyses were performed on micro- 
computer using the CSS: Statistica package (Statsoft, 
Tulsa, U.S.A.). Pre and postoperative results were 
compared using non-parametric Wilcoxon matched 
pairs testing, with pairwise deletion where data 
values were missing. Results were compared with 
controls using the Mann-Whitney U-test. 
Results 
There were 82 patients enrolled in the study (51 male, 
31 female), with a mean age of 70 years. Sixty one 
patients survived to review at 16 weeks postoper- 
ativel)~ giving an overall 16-week mortality rate of 
26%. Five of the 61 survivors were unable to attend for 
review, but were confirmed to be alive by their 
General Practitioners. There were therefore 56 patients 
available for review, who made up the study popula- 
tion, 39 of whom had undergone a prior revascularisa- 
tion procedure. 
There was no evidence of recurrence of critical imb 
ischaemia in the study population, the majority 
having undergone a reconstructive procedure (Table 
1). The mean age of the patients attending for review 
was 69 years, with a range of 50-89 years, and other 
patient characteristics are indicated in Table 2. 
Infrainguinal revascularisation was performed using 
Table 1. Operations carried out in 56 patients with critical limb 
ischaemia 
Operation No. of patients 










Table 2. Patient characteristics in 56 cases of critical limb 
ischaemia, excluding 21 patients dying within 4 months of surger~ 
and five patients lost to fol low up. Cardiovascular disease refers to 
patients with symptomatic ischaemic heart disease or 
cerebrovascular disease 
Characteristic No. of cases (%) 
Male 33 (59) 
Female 23 (41) 
Current/recent smoker 38 (68) 
Prior vascular surgery 34 (61) 
Cardiovascular disease 31 (55) 
Infected or gangrenous limb 25 (45) 
Diabetes 13 (23) 
Hypertension 8 (14) 
Eur J Vasc Endovasc Surg Vol 10, October 1995 
274 K.R. Woodburn et aL 
ipsilateral autogenous leg vein where available, but as 
a consequence of previous revascularisation proce- 
dures 29 patients required insertion of a synthetic graft 
(PTFE or Dacron), while a suitable vein was available 
in only 23 patients. There were no significant differ- 
ences in smoking habits between patients in whom 
vein grafts were used, and those in whom synthetic 
grafts were used (Chi-Square test 0.77(1)). 
Rheological variables 
Following resolution of critical imb ischaemia relative 
blood viscosity fell (p < 0.05, Wilcoxon matched pairs), 
while there was a trend towards a fall in the corrected 
blood viscosity (p = 0.07), together with a significant 
increase in serum albumin (p < 0.005, Table 3). Post- 
operative blood rheology in patients was comparable 
with age-matched population controls, with the 
exception of the white cell count, which remained 
elevated following surgery (p < 0.0005). Exclusion of 
the 25 patients with preoperative limb sepsis or 
necrosis did not alter these observations, with the 
exception of the postoperative fall in red cell aggrega- 
tion, which attained statistical significance in the 
smaller subgroup. 
Table 3. Rheological .variables following successful surgical 
treatment for critical llmb ischaemia in 56 patients, compared with 
levels in an age-matched random population sample. Figures are 
median values (interquartile range) 
Preoperative Postoperative Population 
Variable level level controls 
Whole blood 3.21 2.99 3.24 
viscosity (mPa.s) (2.76-3.50) (2.72-3.60) (2.99-3.70) 
Haematocrit (%) 41 42 44 
(37-45) (38-45) (41-47) 
Corrected blood 3~43 3.27 3.40 
viscosity (mPa.s) (3.22-3.70) (3.06-3.58)t (3.12-3.60) 
Plasma 
viscosity (mPa.s) 1138 1.39 1.36 
(!.31-1.50) (1.33-1.48) (1.3-1.44)§ 
Relative blood 2~50 2.37 2.42 
viscosity (mPa.s) (2.35-2.66) (2.13-2.51)* (2.24-2.61) 
Red cell 4.1 3.7 4.4 
aggregation (units) (3.0-5.5) (3.0-4.4) (3.5-5.0)§ 
White cell 9.6 8.6 6.2 
count (x109/1) (8.0-12.2) (7.0-10.2)* (5.1-7.9):~ 
Serum albumin (g/l) 38 41 n.a. 
(32~42) (37-44)* 
* p < 0.006. 
t p = 0.07, all Wilcoxon matched pairs testing. 
p < 0.0001. 
§ p = 0.07, both Mann-Whitney U-test. 
n.a. = result not available. 
Table 4. Changes in haemostatic variables following successful 
surgical treatment for critical limb ischaemia in 56 patients, 
compared with levels in an age-matched random population 
sample. Figures are median values (interquartile range) 
Preoperative Postoperative Population 
Variable level level controls 
Factor VII 106 113 113 
activity (IU/dl) (79-116) (98-119)* (93-135) 
Fibrinogen (g/l) 4.7 3.8 3.1 
(3.6-5.5) (3.0--4.9)* (2.7-3.8)~ 
von Willebrand 177 153 120 
factor antigen (144-226) (108-197)* (90-147)t 
(IU/dl) 
Tissue plasminogen 8.5 6.9 8.4 
activator antigen (6.5-11.8) (5.5-9.0)* (5.4-10.7) 
(ng/ml) 
Plasminogen activator 103 90 78 
inhibitor activity (77-130) (69-121) (60-92)t 
(% pool) 
Fibrin degradation 285 316 220 
products (ng/ml) (225-510) (192-620) (115-310)t 
* p < 0.006, all Wilcoxon matched pairs testing. 
t p <0.005. 
p =0.02, both Mann-Whitney U-test. 
Haemostatic variables 
Levels of the potential thrombotic mediators plasma 
fibrinogen, vWF, and tPA, all fell significantly follow- 
ing resolution of critical limb ischaemia (Table 4). 
Factor VII levels (analysed after exclusion of patients 
on warfarin therapy) rose significantly following 
surgery, while there was no significant change in the 
levels of cross-linked FDP. Levels of most potential 
thrombotic mediators remained elevated in compar- 
ison with the control population. 
Exclusion of patients with preoperative sepsis or 
tissue necrosis from the analysis did not alter these 
observations, with the exception of the fall in tPA 
levels on resolution of critical limb ischaemia, which 
failed to reach statistical significance after exclusion of 
sepsis and gangrene (p = 0.07). There was, however, a 
trend towards a fall in the postoperative l vels of 
cross-linked FDP following insertion of a vein graft, 
from a median (interquartile range) of 296 ng /ml  
(215-575) to 219 ng /ml  (141-534) (p = 0.09), in contrast 
to the trend towards a rise observed after insertion of 
a synthetic graft (median preoperative l vel 255 ng/  
ml (196--463), postoperative 401 ng /ml  (252-724), 
p = 0.09, Fig. 1). 
Discussion 
Although the patients with critical limb ischaemia 
were not randomly selected, the bias towards infra- 
inguinal disease is in keeping with the distribution of 
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occlusive arterial disease, 2°'21 while most patients with 
critical limb ischaemia would be expected to have 
undergone prior revascularisation surgery. The early 
mortality rate of 26% is high, but there are few figures 
available for comparison, although the mortality rate 
from amputation surgery is reported to range from 
8-18% 22 depending on the site of amputation and 
there is evidence that at least 20% of patients with 
critical imb ischaemia die within I year of diagnosis. 23 
This high mortality probably reflects the high inci- 
dence of symptomatic cardiovascular disease in 
patients with end-stage peripheral arterial disease, 
and the referral pattern to vascular surgical tertiary 
referral centres. 
The 23% incidence of diabetes in the patients 
studied is approximately five times the incidence of 
diabetes in the general population, 24 and reflects the 
high incidence of gangrene in these patients, 25 while 
the observation that over two-thirds of the patients 
were current or recent smokers confirms the strong 
association between smoking and arterial 
disease. 27,28 
Blood theology 
There were surprisingly few changes in rheological 
parameters following resolution of critical imb ischae- 
mia, with only relative blood viscosity (blood viscosity 
corrected for the effects of haematocrit and plasma 
viscosity) showing a significant fall postoperatively. 
This fall in relative blood viscosity (which is a measure 
of the cellular contribution to whole blood viscosity) 
reflects an increase in red cell deformability following 
resolution of critical limb ischaemia, and has pre- 
viously been observed after reconstructive vascular 
surgery. 28 
Serum albumin levels rose significantly following 
resolution of critical imb ischaemia, and this observa- 
tion, together with the lower haematocrit levels 
observed in patients with critical imb ischaemia re in 
contrast o findings in claudicants, 3 suggesting that 
patients with critical limb ischaemia have a haemato- 
logical picture more typical of patients with a chronic 
disease state. 29 This reduction in serum protein levels 
may result in the lowering of plasma viscosity, which 
has previously been shown to be elevated in patients 
with claudication. 3"6 
Plasma fibrinogen 
The association between elevated plasma fibrinogen 
and atherosclerotic vascular disease has been reported 
by a number of authors, 1'3°-32 and there is evidence 
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Fig. I Pre and postoperative FDP levels in 56 patients undergoing surgery for critical imb ischaemia, by type of operation performed. 
(- - -) synthetic median; (- -  ) vein median; (*) amputation; ( + ) synthetic graft; (II) vein graft. 
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severity, and progression, of ischaemia. 8'33-35 This 
study suggests that relief of critical limb ischaemia 
reverses ome of the elevation in plasma fibrinogen 
that is associated with advanced arterial occlusive 
disease, implying that biochemical changes timulat- 
ing fibrinogen synthesis occur in critically ischaemic 
tissues. This fibrinogen synthesis is probably hepatic 
in origin, in response to stimulation of he~paatocytes by 
interleukin-6 (IL-6), 35'36 produced by activated mono- 
cytes 37 and the fall in plasma fibrinogen following 
revascularisation may be related to a reduction in 
white cell activation following resolution of critical 
limb ischaemia. However, correction of critical limb 
ischaemia fails to reduce either white cell count or 
fibrinogen to the levels encountered in an age- 
matched population, and this may contribute to the 
sustained elevation in plasma viscosity. 
Persisting elevation in plasma fibrinogen levels may 
be due to a number of factors including continued 
smoking in the patients studied, 38 and perhaps this 
also explains the continued increase in white cell 
count. The presence of widespread arterial disease at 
other sites may also be associated with elevated 
fibrinogen levels, while there is evidence of a genetic 
influence on plasma fibrinogen 39-41 which may predis- 
pose certain individuals to elevated fibrinogen levels 
regardless of the state of their arterial circulation. 
The postoperative fall in plasma fibrinogen was not 
solely due to resolution of limb sepsis and tissue 
necrosis, although preoperative fibrinogen levels were 
lower in patients where these features were absent, 
confirming that the presence of sepsis and tissue 
necrosis results in elevated plasma fibrinogen. 4~ This 
fall in plasma fibrinogen following resolution of 
critical limb ischaemia has a number of potential 
clinical benefits: elevated plasma fibrinogen is known 
to be an independent risk factor for stroke and 
myocardial infarction, 32 as well as cardiovascular 
mortality, 3° and also to be associated with arterial 
graft occlusion. 1~ The reduction of plasma fibrinogen 
levels 'associated with correction of critical limb 
ischaemia may reduce the risk of these events occur- 
ring post-operatively. 
Fibrin degradation products 
Cross-linked FDP reflect an increase in fibrin turn- 
over. 42 Recent studies have suggested that FDPs are 
elevated in peripheral arterial disease, 35 and that the 
elevation in FDPs is related to the severity of occlusive 
arterial disease. 7'12 Initial analysis of our results 
indicates that fibrin turnover is unaffected by success- 
ful resolution of critical limb ischaemia. However, 
graft type appears to have an effect on FDP levels 
following resolution of critical limb ischaemia. 
The use of autologous vein to revascularise a
critically ischaemic limb produces a trend towards a 
fall in FDPs, with postoperative l vels comparable to 
those in controls, indicating that increased fibrin 
turnover is reversed when the limb is revascularised 
with an autogenous vein graft. This may result from a 
reduction in thrombus formation secondary to stasis, 
as a consequence of an improved arterial inflow. In 
contrast, the use of synthetic graft materials was 
associated with a rise in cross-linked FDP levels, that 
failed to attain statistical significance. A rise in FDP 
levels following insertion of a synthetic graft has 
previously been reported, 35 and this increase in fibrin 
turnover may occur in all patients where a synthetic 
graft is inserted. Previous tudies have shown that the 
innermost layer coating the luminal surface of a 
synthetic graft consists almost entirely of fibrin, 43 and 
these findings suggest hat this layer is continually 
being lysed and reformed, resulting in increased FDP 
levels in patients revascularised with a synthetic graft. 
This increase in fibrin turnover may contribute to the 
greater isk of occlusion in synthetic grafts. 
yon Willebrand factor 
Between 75 and 85% of circulating vWF is derived 
from endothelial cells, the remaining plasma von 
Willebrand factor being derived from platelet activa- 
tion. 44 Elevated levels of vWF are therefore indicative 
of endothelial damage, and have been shown to be 
elevated following direct arterial injur~ 45 and also in 
the presence of peripheral arterial disease. 6'46'47 
Although little is known about the regulation of vWF 
levels, 44 it has been reported that vWF is elevated in 
inflammatory conditions. 48 However the postoper- 
ative reduction in vWF levels observed in this study 
occurred independently of resolution of limb sepsis 
and tissue necrosis. 
Levels of vWF remain higher than in population 
controls following resolution of critical limb ischae- 
mia, and this may be due to widespread disease 
elsewhere in the vascular tree promoting increased 
plasma levels, or perhaps as a consequence ofpersist- 
44 49  ing platelet activation and fibrin turnover. How- 
ever, regardless of aetiolog)6 the persisting elevation in 
vWF levels may have a harmful influence on long- 
term graft survival, as vWF is an essential requirement 
for the development of occlusive arterial thrombi, 5° 
and elevated levels appear to promote increased 
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thrombogenesis. ~6 There is also preliminary evidence 
linking increased vWF levels to a poor outcome 
following infrainguinal revascularisation surgery, lz
Heart Foundation, and Chief Scientists Office, Scottish Home and 
Health Department, for financial support. 
PAl, tPA, and factor VII 
Resolution of critical limb ischaemia leads to a fall in 
tPA and PAI levels, but only the fall in tPA is observed 
after exclusion of cases with preoperative sepsis and 
necrosis. This suggests that conversion of plasmino- 
gen to plasmin could be reduced following resolution 
of critical imb ischaemia, although further studies are 
required. 
Factor VII levels show an inverse relationship with 
fibrinogen levels, 51 and a rise in Factor VII levels 
would be expected to accompany any fall in fibrino- 
gen after resolution of critical limb ischaemia. It 
appears that surgical resolution of critical imb ischae- 
mia results in the return of Factor VII levels to normal 
population levels, presumably as result of resolution 
of inflammatory changes associated with critical limb 
ischaemia, 5zthat reduce Factor VII levels. 
Summary 
This study confirms that increased fibrinogen, fibrin 
turnover, and vWF levels are associated with critical 
limb ischaemia. These alterations may promote a 
thrombogenic environment hat contributes to an 
increased risk of cerebrovascular, cardiovascular, and 
peripheral vascular occlusive events in patients with 
critical imb ischaemia. Many of the changes observed 
in this study indicate that critical limb ischaemia 
results in biochemical alterations that are typical of 
chronic inflammatory conditions. Although these 
alterations are partly reversible, there appear to be 
persisting elevations in plasma fibrinogen, FDP, and 
vWF levels following revascularisation that may 
adversely affect longer-term graft and patient sur- 
vival while the trend towards increasing fibrin turn- 
over following insertion of a synthetic graft requires 
further study. 
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